Related Experiment Videos
JAK-STAT-mediated chronic inflammation impairs cytotoxic T lymphocyte activation to decrease anti-PD-1 immunotherapy
Chunwan Lu1, Asif Talukder2, Natasha M Savage3
1Department of Biochemistry and Molecular Biology, Medical College of Georgia, Augusta, GA, USA; Georgia Cancer Center, Augusta, GA, USA; Charlie Norwood VA Medical Center, Augusta, GA, USA.
Oncoimmunology
|April 14, 2017
Summary
Pancreatic cancer resists immunotherapy by activating JAK-STAT signaling, which suppresses T cells. Inhibiting this pathway with Ruxolitinib restores T cell activity, overcoming resistance to anti-PD-1 therapy.
Area of Science:
- Oncology
- Immunology
- Cancer Research
Background:
- Pancreatic cancer exhibits resistance to immune checkpoint blockade immunotherapy.
- Chronic inflammation and JAK-STAT pathway activation are key features of pancreatic cancer progression.
- Sustained JAK-STAT signaling is hypothesized to suppress cytotoxic T lymphocyte (CTL) activation, counteracting anti-PD-1 immunotherapy.
Purpose of the Study:
- To investigate the role of JAK-STAT signaling in pancreatic cancer's resistance to immunotherapy.
- To determine if inhibiting JAK-STAT signaling can enhance the efficacy of anti-PD-1 immunotherapy in pancreatic cancer.
Main Methods:
- Utilized an orthotopic pancreatic cancer mouse model.
- Administered JAK-STAT inhibitor Ruxolitinib.
- Assessed CTL infiltration, activation, and immune response.
- Evaluated the impact of Ruxolitinib on PD-L1 expression and cytokine production.
- Conducted experiments in T-cell-deficient and IFNγ-deficient mice.
Main Results:
- Ruxolitinib selectively inhibited STAT1 and STAT3 activation, increasing CTL infiltration and promoting a Tc1/Th1 immune response.
- Ruxolitinib's tumor suppressive effects were dependent on T cells and IFNγ.
- Interferons upregulate PD-L1 expression via JAK-STAT signaling in pancreatic tumor cells.
- STAT3 inhibition reduced immunosuppressive cytokines, enhancing T cell activation and effector function.
- Ruxolitinib significantly improved the efficacy of anti-PD-1 immunotherapy.
Conclusions:
- JAK-STAT signaling inhibition is a viable strategy to overcome pancreatic cancer resistance to anti-PD-1 immunotherapy.
- Ruxolitinib effectively reduces tumor microenvironment inflammation, enhancing CTL infiltration and activation.
- Targeting the JAK-STAT pathway can restore anti-tumor immunity in pancreatic cancer.